My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
May 2012
Global ID
Combination HIV Drug Recommended for Approval to Prevent HIV Infection

Check out Science Speaks for updates on recent recommendations from two Food and Drug Administration advisory committees to approve a rapid, at-home HIV test for sale over the counter and to approve the use of a combination HIV drug that includes emtricitabine and tenofovir as pre-exposure prophylaxis (PrEP) for high-risk individuals not infected with HIV to reduce the risk of sexually acquired HIV infection. Science Speaks is the blog of the Center for Global Health Policy.

More recent news from the blog:


How useful is this article?

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
Guidance for Increasing Adult Pneumococcal Vaccination Rates
Drug Approvals, Recalls, Adverse Events Update
Clinical Practice Management
Legislation Would Repeal Flawed Physician Payment Formula
Physician Groups: “Meaningful Use” Rule Should Encourage EHR Use
Global ID
Combination HIV Drug Recommended for Approval to Prevent HIV Infection
Global Health Funding Updates from Capitol Hill
Study: HIV Funding Does Not Undermine Response to Other Diseases in Rwanda
Policy and Advocacy
Society Continues to Push for Adult Immunization
IDSA, HIVMA Defend Prevention and Public Health Fund
IDSA Comments on FDA Draft Guidance for Developing cUTI Drugs
Your Colleagues
Check Out “My IDSA” for Latest Member News
Education & Resources
Meet Your Match With the ID/HIV Career Center
Top Stories
Updated Guideline for Diabetic Foot Infections Now Available
Antibiotic Incentives Legislation Nearing Passage
EIN Update: Cryptococcal Disease and Diagnostic Issues
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.